SARS-CoV-2 reinfection trends in South Africa: analysis of routine surveillance data

@inproceedings{Pulliam2021SARSCoV2RT,
  title={SARS-CoV-2 reinfection trends in South Africa: analysis of routine surveillance data},
  author={J. R. C. Pulliam and Cari van Schalkwyk and Nelesh P. Govender and Anne von Gottberg and Cheryl Cohen and Michelle J. Groome and Jonathan Dushoff and K. Mlisana and Harry Moultrie},
  booktitle={medRxiv},
  year={2021}
}
Objective: To examine whether SARS-CoV-2 reinfection risk has changed through time in South Africa, in the context of the emergence of the Beta and Delta variants Design: Retrospective analysis of routine epidemiological surveillance data Setting: Line list data on SARS-CoV-2 with specimen receipt dates between 04 March 2020 and 30 June 2021, collected through South Africa's National Notifiable Medical Conditions Surveillance System Participants: 1,551,655 individuals with laboratory-confirmed… 
2 Citations
Covid-19: South Africa’s surge in cases deepens alarm over omicron variant
In the outbreak’s epicentre—Gauteng, the populous province that contains Pretoria and Johannesburg—74% of samples sequenced from the last three weeks of November involved the new variant. This
How bad is Omicron? What scientists know so far.
TLDR
It might take scientists weeks to paint a more complete picture of Omicron, and to gain an understanding of its transmissibility and severity, as well as its potential to evade vaccines and cause reinfections.

References

SHOWING 1-10 OF 22 REFERENCES
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
TLDR
The findings could inform decisions on which groups should be vaccinated and advocate for vaccination of previously infected individuals because natural protection, especially among older people, cannot be relied on.
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
TLDR
This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.
Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021
Background: Population-level estimates of the prevalence of anti-SARS-CoV-2 antibody positivity (seroprevalence) are crucial epidemiological indicators for tracking the Covid-19 epidemic. Such data
Quantifying the risk of SARS‐CoV‐2 reinfection over time
TLDR
Data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection, however, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain.
Detection of a SARS-CoV-2 variant of concern in South Africa
TLDR
A newly arisen lineage of SARS-CoV-2 is described that is defined by eight mutations in the spike protein, including three substitutions at residues in its receptor-binding domain that may have functional importance.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
TLDR
Sera from individuals having received one dose of Pfizer or AstraZeneca vaccines barely inhibited variant Delta, and it was found that variant Delta spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
TLDR
The BNT162b2 vaccine was shown to have 95% efficacy against coronavirus disease 2019 (Covid-19) and administration of a single dose is now being considered in Israel.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
TLDR
The recent emergence of new SARS-CoV-2 variants B.1.2.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
TLDR
The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
TLDR
Preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages is provided, with the observed effective neutralization of first wave virus by 501Y.V2 infection elicited plasma.
...
1
2
3
...